Thrombo-Hemorrhagic Complications in Myeloproliferative Neoplasms: Etiology, Pathobiology, and Therapeutic Considerations
<p id="p1">Myeloproliferative neoplasms (MPN) are characterized by the abnormal clonal proliferation of hematopoietic progenitor cells in the bone marrow. The three major types of MPNs are polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Specific mutations in...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2024
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/89726 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | <p id="p1">Myeloproliferative neoplasms (MPN) are characterized by the abnormal clonal proliferation of hematopoietic progenitor cells in the bone marrow. The three major types of MPNs are polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Specific mutations in the Janus Kinase 2 (JAK2), calreticulin (CALR), and thrombopoietin receptor (MPL) genes are the primary drivers of the MPNs. The clinical and pathophysiological characteristics of MPNs vary depending on the type of MPN, with underlying standard features such as increased platelet activation and altered hemostasis. This imbalance contributes to the increased tendency for both thrombotic and fibrinolytic events in patients with MPN, which negatively impacts life expectancy and quality of life. This chapter will discuss the mechanisms accentuating the hypercoagulability and fibrinolytic states in MPNs. We also review the current therapies that treat the thrombosis associated with MPNs.</p> |
|---|---|
| ISBN: | 978-0-85014-468-0 |
| DOI: | 10.5772/intechopen.115533 |